T1	Participants 756 815	720 patients screened, 306 eligible patients were enrolled.
T2	Participants 584 612	51 centres in nine countries
T3	Participants 638 752	one or more relapses in the year before entry and at least one gadolinium enhancing (GdE) lesion on screening MRI.
T4	Participants 277 392	patients with relapsing-remitting multiple sclerosis was well tolerated and reduced the formation of active lesions
